N/A N=69 IFI16 is a Periodontitis Modulating Protein
Severe Periodontitis · Acute Inflammatory Response
Primary: Change in Absent in Melanoma 2 (AIM2) mRNA Expression Levels — 0.37; 0.65 fold change — p=0.3
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=39 Exercise After Clinically Significant Weight Loss
Obesity · Sedentary Lifestyle · Insulin Resistance
Primary: Change in Weight — 0.7; -1.5 kg — p=0.256
Phase 2 N=43 Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer
Prostatic Neoplasms
Primary: Number of Patients With Immunological Response — 9 Participants
Phase 3 N=3,065 Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study
Heart Failure · Iron-deficiency
Primary: Number of Deaths — 131; 158 Participants
N/A N=67 A Pilot Study to Assess the Efficacy and Safety of Various Vibrating Capsule Modes
Constipation
Primary: CSBM1- an Increase of at Least One Weekly Complete Spontaneous Bowel Movement (CSBM) During at Least 6 of the 8 Weeks of Treatment — 7; 7; 9 Participants
N/A N=28 Development and Piloting an Avatar-based Intervention to Support Patients Undergoing Stem Cell Transplantation
Hematopoietic Cell Transplantation
Primary: Number of Participants Retained — 18 Participants
Phase 4 N=150 Comparison of Nebulized Ketamine to Intravenous Sub-Dissociative Dose Ketamine for Pain
Pain
Primary: Change in in Pain Score at 30 Minutes — 4.7; 4.5 score on a scale
Phase 2 N=25 A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
Sphingomyelin Lipidosis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs)…
Phase 2 N=32 Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection
Mycobacterium Infections, Nontuberculous
Primary: Number of Participants With Sputum Culture Conversion to Negative — 2; 3 Participants
Phase 2 N=136 Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
Parkinson Disease
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Study Drug — 9.1; 17.8; 19.1 Percentage of participants
N/A N=47 Pilot Study of High-flow Humidified Nasal Oxygen During Breaks From Noninvasive Ventilation
Acute Respiratory Failure · Treatment With Noninvasive Positive Pressure Ventilation
Primary: Length of Stay on Noninvasive Ventilation (NIV) — 1404; 1386 Minutes
N/A N=21 Time Course Adaptations Using Deuterated Creatine (D3Cr) Method
Sarcopenia
Primary: Muscle Mass — 3.47; 1.19 Kg — p=0.03
N/A N=11 Mixed Reality Based System to Manage Phantom Pain Phantom Pain for Patients With Lower Limb Amputation
Phantom Limb Pain
Primary: Change in Numerical Rating Scale — 1.75; 1.125 score on a scale — p=0.011
N/A N=23 App-Assisted Day Reconstruction to Reduce Logistic Toxicity in Cancer
Cancer
Primary: Interviews — 20 Interviews
N/A N=243 Comparing Group Therapies for Veterans With Depression and PTSD
Major Depressive Disorder · Posttraumatic Stress Disorder
Primary: Depression Anxiety Stress Scale (DASS-Depression) — 10.6; 11.0; 8.8; 8.1 units on a scale — p=.025